A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Recruiting now · Phase 1

Conditions studied: Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease

In brief

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.

Key facts

Study ID

NCT06164730

Run by

Verve Therapeutics, Inc.

People needed

85

Starts

2024-04-30

Expected to finish

2027-08-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of HeFH or premature CAD

You may not qualify if…

• Homozygous familial hypercholesterolemia
• Active or history of chronic liver disease
• Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
• Clinically significant or abnormal laboratory values as defined by the protocol

Where it is running

• Clinical Study Center — Dothan, Alabama, United States (enrolling)
• Clinical Study Center — Pomona, California, United States (enrolling)
• Clinical Study Center — Boca Raton, Florida, United States (enrolling)
• Clinical Study Center — Jacksonville, Florida, United States (enrolling)
• Clinical Study Center — Winter Park, Florida, United States (enrolling)
• Clinical Study Center — Indianapolis, Indiana, United States (enrolling)
• Clinical Study Center — High Point, North Carolina, United States (enrolling)
• Clinical Study Center — Philadelphia, Pennsylvania, United States (enrolling)
• Clinical Study Center — DeSoto, Texas, United States (enrolling)
• Clinical Study Center — Renton, Washington, United States (enrolling)
• Clinical Study Center — Adelaide, Australia (enrolling)
• Clinical Study Center — Melbourne, Australia (enrolling)
• Clinical Study Center — Sydney, Australia (enrolling)
• Clinical Study Center — Chicoutimi, Canada (enrolling)
• Clinical Study Center — Hamilton, Canada (enrolling)
• Clinical Study Center — Montreal, Canada (enrolling)
• Clinical Study Center — Québec, Canada (enrolling)
• Clinical Study Center — Toronto, Canada (enrolling)
• Clinical Study Center — Vancouver, Canada (enrolling)
• Clinical Study Center — Rehovot, Israel (enrolling)
• Clinical Study Center — Christchurch, New Zealand (enrolling)
• Clinical Study Center — Birmingham, United Kingdom (enrolling)
• Clinical Study Center — Cambridge, United Kingdom (enrolling)
• Clinical Study Center — Edinburgh, United Kingdom (enrolling)
• Clinical Study Center — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.